Selected transactions
To reflect healthcare trailblazers, we are shifting our focus to an integrative healthcare approach from therapeutics to personalized and preventive medicine, anti- and better-aging, healthy well-being and lifestyle.
Please find below selected transactions completed by WINDOME BANKING PARTNERS’ employees while at other Firms, except for the Suisselle-Sihuan Pharma Deal (June 2023).
Acquisition of the over-the-counter (“OTC”) Zantac anti-ulcerant gastrointestinal products from Johnson & Johnson (J&J).
Divestiture of Toyama facility, Boehringer Ingelheim’s dedicated plant for the manufacturing of lyophilized solutions to Yamanouchi-Fujisawa (now Astellas) and concurrent entry into a long-term toll manufacturing agreement via carve-out (“Bunkatsu procedure”).
Divestiture of Pharmaton SA, Lugano and Boehringer Ingelheim’s worldwide Natural Health Phyto-based Nutraceuticals, Vitamins and Mineral Supplements to Amway.
Completed divestiture of Boehringer Ingelheim’s ectoparasiticides Animal Health Business to Elanco.
Completed divestiture of a broad-spectrum antibiotic (“Romifidine”) for feed use in Animal Health.
Completed divestiture of Boehringer Ingelheim’s and SSP’s portfolio of Korean and Japanese subsidiaries.
Completed divestiture via carve-out of Nippon Boehringer Ingelheim’s prescription generics business in Japan (Total sales €100m in 2003) including a guarantee payment by Boehringer Ingelheim for a 2 Year post-closing employment continuation.
Completed the 100% acquisition of German respiratory medical devices company Steag MicroParts GmbH, Dortmund.
Completed the divestiture of 5 US OTC Natural Health multivitamin brands to Bayer AG.
Completed acquisition of ID Lelystad’s Animal Health vaccine business.
Completed acquisition of Novartis’s OTC Laxative brand Dulcolax.
Exclusive financial advisor to MorphoSys in signing collaboration partnership with Boehringer Ingelheim.